Oakridge Doubles Annual Cash Receipts to $2.46M, Expands Partner Network

Oakridge International reported robust revenue growth and expanded its partner network in Q4 2025, underpinning a promising outlook in healthcare technology. The company also advanced product innovation aligned with new industry standards.

  • Q4 cash receipts of $774k, annual total $2.458 million, doubling prior year
  • Expanded authorised partner agreements with multi-year growth targets
  • Strong sales pipeline with notable wins in aged care and health sectors
  • Product development focused on new apps and AS8311-2024 nurse call standards
  • Ongoing legal discussions with Teko International over potential claim
An image related to Oakridge International Limited
Image source middle. ©

Financial Performance and Growth Momentum

Oakridge International Limited (ASX, OAK), an Australian healthcare technology company specialising in IoT-enabled nurse call and assistive solutions, delivered a solid quarter ending June 2025. The company reported cash receipts from customers of $774,000 for Q4 and a total of $2.458 million for the full year, significantly outperforming the previous year’s $1.087 million and exceeding budget expectations. This financial momentum reflects strong operational execution and growing market demand across hospitals, aged care, and disability sectors.

Underlying this growth is a robust pipeline of highly probable sales quotes and orders, particularly in key Australian states. Oakridge’s ability to convert these opportunities into project completions has been a key driver of its revenue expansion, signaling sustained commercial traction.

Strategic Partnerships and Market Expansion

During the quarter, Oakridge expanded its authorised partner network through new agreements designed to accelerate market penetration over multiple years. These partnerships, combined with ongoing collaboration with established channel partners, have strengthened Oakridge’s distribution reach and sales capabilities in the health and aged care sectors.

The company is actively seeking additional value-aligned partners to further optimise its service footprint. Importantly, Oakridge integrates partner and end-user feedback into its product development roadmap, ensuring its solutions remain competitive and aligned with evolving customer needs.

Product Innovation and Operational Enhancements

Innovation remains a strategic focus, with Oakridge advancing its core platforms, including new Android and iOS applications and enhanced real-time location system (RTLS) integration. The NuCaMS Enterprise Version and other next-generation offerings are being developed in alignment with the upcoming AS8311-2024 nurse call system standards, positioning the company well for future regulatory compliance and market demand.

Operationally, Oakridge has expanded its technical and development teams and completed a successful transition to Zoho Books for invoicing and CRM, improving internal efficiencies. Marketing efforts have also intensified, with a data-driven digital strategy boosting online engagement and lead generation.

Legal Considerations and Outlook

Oakridge disclosed ongoing discussions with Teko International Limited regarding a potential legal claim related to alleged misrepresentations by previous directors. While the company acknowledges some exposure, it is actively negotiating with legal advisors to seek a favourable outcome. This issue introduces some uncertainty but has not overshadowed the company’s operational progress.

Looking ahead, Oakridge’s strong project pipeline, continuous product innovation, and expanding partner network position it well for sustained growth in the healthcare technology sector. The company’s strategic initiatives and financial discipline suggest a positive trajectory despite the legal cloud.

Bottom Line?

Oakridge’s solid quarter and strategic partnerships set the stage for growth, but legal risks warrant close investor attention.

Questions in the middle?

  • How will the potential legal claim from Teko International impact Oakridge’s financial position?
  • What is the timeline for commercial rollout of products aligned with the AS8311-2024 standards?
  • Can Oakridge sustain its sales pipeline conversion rates amid increasing competition?